St. Baldrick’s commits $8 million to SU2C Pediatric Cancer Dream Team

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The work of the Stand Up to Cancer-St. Baldrick’s Foundation Pediatric Cancer Dream Team, launched in 2013 to help develop new immunotherapy approaches to high-risk childhood cancers, will continue with a commitment of $8 million from the St. Baldrick’s Foundation, the world’s largest private funder of childhood cancer research grants. To further the impact of this gift, the eight institutions that make up the consortium have committed matching dollars to a total of $16 million.

Continuing as co-leaders of the newly charged St. Baldrick’s-Stand Up to Cancer Pediatric Cancer Dream Team are John Maris, pediatric oncologist and holder of the Giulio D’Angio Chair in Neuroblastoma Research at Children’s Hospital of Philadelphia, and Crystal Mackall, professor of pediatrics (hematology and oncology) at Stanford University and associate director of the Stanford Cancer Institute.

St. Baldrick’s and Stand Up to Cancer initially provided the Dream Team, consisting of more than 150 researchers at eight institutions, with $14.5 million over a four-year term beginning in 2013. The Dream Team worked to improve and expand immunotherapy in childhood cancers.

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login